Forbes May 25, 2024
Robert Hart

Topline

Novo Nordisk’s weight loss injection semaglutide — the ingredient inside its wildly popular drugs Ozempic and Wegovy — could also help protect the kidneys, according to new research, a finding that bolsters the growing public health case for the drug amid ongoing concerns over costs and short supplies.

Key Facts

Tangent

Kidney injury has been reported as a potential side effect of taking semaglutide and is indicated as a potential risk on the Food and Drug Administration label for the drug. In this latest trial, however, the researchers said they found no increased risk of acute kidney injury linked to semaglutide treatment. This held regardless of baseline kidney function, the researchers added.

News Peg

Novo Nordisk ended a separate...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Physician, Provider, Survey / Study, Trends
Roche partners with RNA editing biotech Ascidian
340B drug program spending up 19% + 6 other notes
Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
How Multi-Omics Is Empowering The Discovery Of Cancer Biomarkers

Share This Article